Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symp...
Saved in:
| Published in | Journal of asthma and allergy Vol. 16; pp. 915 - 932 |
|---|---|
| Main Authors | , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Dove Medical Press Limited
30.09.2023
Dove Dove Medical Press |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1178-6965 1178-6965 |
| DOI | 10.2147/JAA.S413064 |
Cover
| Abstract | Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control versus placebo in adults and adolescents with severe, uncontrolled asthma. We assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (NPs) in the 2 years before randomization in NAVIGATOR. Methods: Patients with severe asthma (N=1059) were randomized (1:1) and received tezepelumab 210 mg or placebo every 4 weeks subcutaneously for 52 weeks. Prespecified exploratory analyses included: AAER over 52 weeks and changes from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 second, Sino-Nasal Outcome Test (SNOT)-22 scores, and asthma control and health-related quality life (HRQoL) outcomes in NP subgroups. Changes from baseline in fractional exhaled nitric oxide (FeNO), blood eosinophil counts, total immunoglobulin E (IgE), eosinophil-derived neurotoxin (EDN), matrix metalloproteinase-10 (MMP-10), and serum interleukin (IL)-5, IL-6, IL-8 and IL-13 were assessed (post hoc). Results: Tezepelumab reduced the AAER over 52 weeks versus placebo by 85% (95% confidence interval [CI]: 72, 92; n=118) and 51% (95% CI: 40, 60; n=941) in patients with and without NPs, respectively. At week 52, tezepelumab improved lung function, asthma control and HRQoL versus placebo in patients with and without NPs. Tezepelumab reduced SNOT-22 total scores (least-squares mean difference versus placebo [95% CI]) in patients with NPs at 28 weeks (-12.57 points [-19.40, -5.73]) and 52 weeks (-10.58 points [-17.75, -3.41]). At week 52, tezepelumab reduced blood eosinophil counts and FeNO, IgE, IL-5, IL-13, EDN and MMP-10 levels versus placebo, irrespective of NP status. Conclusion: Tezepelumab resulted in clinically meaningful improvements in sino-nasal symptoms and asthma outcomes in patients with severe asthma with comorbid NPs. Plain Language Summary: Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing, coughing, wheezing and shortness of breath. Approximately 41% of patients with severe asthma also have chronic rhinosinusitis with nasal polyps, a condition that affects the upper airways and sinuses. Nasal polyps are painless soft growths inside your nose that can keep growing if not treated. Symptoms include nasal congestion with mucus, facial pain and a reduced sense of smell or taste. People with both severe asthma and nasal polyps often have severe symptoms. Thymic stromal lymphopoietin (TSLP) is a signaling molecule released by cells lining the airways in response to airborne triggers, such as smoke, pollen and viruses. TSLP activates several pathways that cause inflammation in the airways, leading to asthma symptoms. Tezepelumab is a biologic treatment that targets the very start of these inflammatory pathways by blocking TSLP. The 1-year-long clinical trial called "NAVIGATOR" reported that tezepelumab reduced asthma attacks and improved lung function and asthma symptom control compared with placebo in patients with severe asthma that was not controlled with their current medicines. This analysis of data from NAVIGATOR looked at patients with both severe asthma and nasal polyps, showing that tezepelumab treatment improved sino-nasal symptoms compared with placebo. Tezepelumab also reduced asthma attacks and improved asthma symptoms, regardless of a patient's medical history of nasal polyps. The effects of tezepelumab in patients with severe nasal polyps are being investigated in another clinical trial called "WAYPOINT". Keywords: chronic rhinosinusitis, nasal polyps, SNOT-22, thymic stromal lymphopoietin |
|---|---|
| AbstractList | Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing, coughing, wheezing and shortness of breath. Approximately 41% of patients with severe asthma also have chronic rhinosinusitis with nasal polyps, a condition that affects the upper airways and sinuses. Nasal polyps are painless soft growths inside your nose that can keep growing if not treated. Symptoms include nasal congestion with mucus, facial pain and a reduced sense of smell or taste. People with both severe asthma and nasal polyps often have severe symptoms.
Thymic stromal lymphopoietin (TSLP) is a signaling molecule released by cells lining the airways in response to airborne triggers, such as smoke, pollen and viruses. TSLP activates several pathways that cause inflammation in the airways, leading to asthma symptoms. Tezepelumab is a biologic treatment that targets the very start of these inflammatory pathways by blocking TSLP.
The 1-year-long clinical trial called “NAVIGATOR” reported that tezepelumab reduced asthma attacks and improved lung function and asthma symptom control compared with placebo in patients with severe asthma that was not controlled with their current medicines. This analysis of data from NAVIGATOR looked at patients with both severe asthma and nasal polyps, showing that tezepelumab treatment improved sino-nasal symptoms compared with placebo. Tezepelumab also reduced asthma attacks and improved asthma symptoms, regardless of a patient’s medical history of nasal polyps. The effects of tezepelumab in patients with severe nasal polyps are being investigated in another clinical trial called “WAYPOINT”. Tanya M Laidlaw1,2 *, Andrew Menzies-Gow3 *, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil Martin,12,13 Ayman Megally,14 Bhavini Parikh,14 Sylvia Vong,15 Tobias Welte,16 Jonathan Corren17 1Jeff and Penny Vinik Center for Allergic Diseases Research, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, Boston, MA, USA; 2Department of Medicine, Harvard Medical School, Boston, MA, USA; 3Royal Brompton and Harefield Hospitals, School of Immunology and Microbial Sciences, King’s College London, London, UK; 4Global Development, Inflammation, R&D, Amgen, Thousand Oaks, CA, USA; 5Department of Otolaryngology, Head and Neck Surgery, Eastern Virginia Medical School, Norfolk, VA, USA; 6Biometrics, Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA; 7Cytel Inc, Waltham, MA, USA; 8Divisions of Pulmonary and Critical Care Medicine and Allergy and Clinical Immunology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 9Evidence Based Medical Educator Inc., Toronto, ON, Canada; 10Toronto Allergy and Asthma Clinic, Toronto, ON, Canada; 11Global Medical Affairs, Amgen, Thousand Oaks, CA, USA; 12Respiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 13University of Leicester, Leicester, UK; 14Late-Stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA; 15Translational Science and Experimental Medicine, Early Respiratory and Immunology, AstraZeneca, Gaithersburg, MD, USA; 16Department of Respiratory Medicine and German Center for Lung Research, Hannover Medical School, Hannover, Germany; 17David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA, USA*These authors contributed equally to this workCorrespondence: Tanya M Laidlaw, Jeff and Penny Vinik Center for Allergic Diseases Research, Division of Allergy and Clinical Immunology, Brigham and Women’s Hospital, 60 Fenwood Road, Boston, MA, 02115, USA, Email tlaidlaw@bwh.harvard.eduPurpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control versus placebo in adults and adolescents with severe, uncontrolled asthma. We assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (NPs) in the 2 years before randomization in NAVIGATOR.Methods: Patients with severe asthma (N=1059) were randomized (1:1) and received tezepelumab 210 mg or placebo every 4 weeks subcutaneously for 52 weeks. Prespecified exploratory analyses included: AAER over 52 weeks and changes from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 second, Sino-Nasal Outcome Test (SNOT)-22 scores, and asthma control and health-related quality life (HRQoL) outcomes in NP subgroups. Changes from baseline in fractional exhaled nitric oxide (FeNO), blood eosinophil counts, total immunoglobulin E (IgE), eosinophil-derived neurotoxin (EDN), matrix metalloproteinase-10 (MMP-10), and serum interleukin (IL)-5, IL-6, IL-8 and IL-13 were assessed (post hoc).Results: Tezepelumab reduced the AAER over 52 weeks versus placebo by 85% (95% confidence interval [CI]: 72, 92; n=118) and 51% (95% CI: 40, 60; n=941) in patients with and without NPs, respectively. At week 52, tezepelumab improved lung function, asthma control and HRQoL versus placebo in patients with and without NPs. Tezepelumab reduced SNOT-22 total scores (least-squares mean difference versus placebo [95% CI]) in patients with NPs at 28 weeks (– 12.57 points [– 19.40, – 5.73]) and 52 weeks (– 10.58 points [– 17.75, – 3.41]). At week 52, tezepelumab reduced blood eosinophil counts and FeNO, IgE, IL-5, IL-13, EDN and MMP-10 levels versus placebo, irrespective of NP status.Conclusion: Tezepelumab resulted in clinically meaningful improvements in sino-nasal symptoms and asthma outcomes in patients with severe asthma with comorbid NPs.Graphical Abstract: Plain Language Summary: Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing, coughing, wheezing and shortness of breath. Approximately 41% of patients with severe asthma also have chronic rhinosinusitis with nasal polyps, a condition that affects the upper airways and sinuses. Nasal polyps are painless soft growths inside your nose that can keep growing if not treated. Symptoms include nasal congestion with mucus, facial pain and a reduced sense of smell or taste. People with both severe asthma and nasal polyps often have severe symptoms.Thymic stromal lymphopoietin (TSLP) is a signaling molecule released by cells lining the airways in response to airborne triggers, such as smoke, pollen and viruses. TSLP activates several pathways that cause inflammation in the airways, leading to asthma symptoms. Tezepelumab is a biologic treatment that targets the very start of these inflammatory pathways by blocking TSLP.The 1-year-long clinical trial called “NAVIGATOR” reported that tezepelumab reduced asthma attacks and improved lung function and asthma symptom control compared with placebo in patients with severe asthma that was not controlled with their current medicines. This analysis of data from NAVIGATOR looked at patients with both severe asthma and nasal polyps, showing that tezepelumab treatment improved sino-nasal symptoms compared with placebo. Tezepelumab also reduced asthma attacks and improved asthma symptoms, regardless of a patient’s medical history of nasal polyps. The effects of tezepelumab in patients with severe nasal polyps are being investigated in another clinical trial called “WAYPOINT”.Keywords: chronic rhinosinusitis, nasal polyps, SNOT-22, thymic stromal lymphopoietin Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control versus placebo in adults and adolescents with severe, uncontrolled asthma. We assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (NPs) in the 2 years before randomization in NAVIGATOR. Methods: Patients with severe asthma (N=1059) were randomized (1:1) and received tezepelumab 210 mg or placebo every 4 weeks subcutaneously for 52 weeks. Prespecified exploratory analyses included: AAER over 52 weeks and changes from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 second, Sino-Nasal Outcome Test (SNOT)-22 scores, and asthma control and health-related quality life (HRQoL) outcomes in NP subgroups. Changes from baseline in fractional exhaled nitric oxide (FeNO), blood eosinophil counts, total immunoglobulin E (IgE), eosinophil-derived neurotoxin (EDN), matrix metalloproteinase-10 (MMP-10), and serum interleukin (IL)-5, IL-6, IL-8 and IL-13 were assessed (post hoc). Results: Tezepelumab reduced the AAER over 52 weeks versus placebo by 85% (95% confidence interval [CI]: 72, 92; n=118) and 51% (95% CI: 40, 60; n=941) in patients with and without NPs, respectively. At week 52, tezepelumab improved lung function, asthma control and HRQoL versus placebo in patients with and without NPs. Tezepelumab reduced SNOT-22 total scores (least-squares mean difference versus placebo [95% CI]) in patients with NPs at 28 weeks (-12.57 points [-19.40, -5.73]) and 52 weeks (-10.58 points [-17.75, -3.41]). At week 52, tezepelumab reduced blood eosinophil counts and FeNO, IgE, IL-5, IL-13, EDN and MMP-10 levels versus placebo, irrespective of NP status. Conclusion: Tezepelumab resulted in clinically meaningful improvements in sino-nasal symptoms and asthma outcomes in patients with severe asthma with comorbid NPs. Plain Language Summary: Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing, coughing, wheezing and shortness of breath. Approximately 41% of patients with severe asthma also have chronic rhinosinusitis with nasal polyps, a condition that affects the upper airways and sinuses. Nasal polyps are painless soft growths inside your nose that can keep growing if not treated. Symptoms include nasal congestion with mucus, facial pain and a reduced sense of smell or taste. People with both severe asthma and nasal polyps often have severe symptoms. Thymic stromal lymphopoietin (TSLP) is a signaling molecule released by cells lining the airways in response to airborne triggers, such as smoke, pollen and viruses. TSLP activates several pathways that cause inflammation in the airways, leading to asthma symptoms. Tezepelumab is a biologic treatment that targets the very start of these inflammatory pathways by blocking TSLP. The 1-year-long clinical trial called "NAVIGATOR" reported that tezepelumab reduced asthma attacks and improved lung function and asthma symptom control compared with placebo in patients with severe asthma that was not controlled with their current medicines. This analysis of data from NAVIGATOR looked at patients with both severe asthma and nasal polyps, showing that tezepelumab treatment improved sino-nasal symptoms compared with placebo. Tezepelumab also reduced asthma attacks and improved asthma symptoms, regardless of a patient's medical history of nasal polyps. The effects of tezepelumab in patients with severe nasal polyps are being investigated in another clinical trial called "WAYPOINT". Keywords: chronic rhinosinusitis, nasal polyps, SNOT-22, thymic stromal lymphopoietin Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control versus placebo in adults and adolescents with severe, uncontrolled asthma. We assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (NPs) in the 2 years before randomization in NAVIGATOR.PurposeTezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized asthma exacerbation rates (AAERs) versus placebo, irrespective of baseline disease characteristics, and improved lung function and symptom control versus placebo in adults and adolescents with severe, uncontrolled asthma. We assessed the efficacy of tezepelumab in patients with severe asthma with or without nasal polyps (NPs) in the 2 years before randomization in NAVIGATOR.Patients with severe asthma (N=1059) were randomized (1:1) and received tezepelumab 210 mg or placebo every 4 weeks subcutaneously for 52 weeks. Prespecified exploratory analyses included: AAER over 52 weeks and changes from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 second, Sino-Nasal Outcome Test (SNOT)-22 scores, and asthma control and health-related quality life (HRQoL) outcomes in NP subgroups. Changes from baseline in fractional exhaled nitric oxide (FeNO), blood eosinophil counts, total immunoglobulin E (IgE), eosinophil-derived neurotoxin (EDN), matrix metalloproteinase-10 (MMP-10), and serum interleukin (IL)-5, IL-6, IL-8 and IL-13 were assessed (post hoc).MethodsPatients with severe asthma (N=1059) were randomized (1:1) and received tezepelumab 210 mg or placebo every 4 weeks subcutaneously for 52 weeks. Prespecified exploratory analyses included: AAER over 52 weeks and changes from baseline to week 52 in pre-bronchodilator forced expiratory volume in 1 second, Sino-Nasal Outcome Test (SNOT)-22 scores, and asthma control and health-related quality life (HRQoL) outcomes in NP subgroups. Changes from baseline in fractional exhaled nitric oxide (FeNO), blood eosinophil counts, total immunoglobulin E (IgE), eosinophil-derived neurotoxin (EDN), matrix metalloproteinase-10 (MMP-10), and serum interleukin (IL)-5, IL-6, IL-8 and IL-13 were assessed (post hoc).Tezepelumab reduced the AAER over 52 weeks versus placebo by 85% (95% confidence interval [CI]: 72, 92; n=118) and 51% (95% CI: 40, 60; n=941) in patients with and without NPs, respectively. At week 52, tezepelumab improved lung function, asthma control and HRQoL versus placebo in patients with and without NPs. Tezepelumab reduced SNOT-22 total scores (least-squares mean difference versus placebo [95% CI]) in patients with NPs at 28 weeks (-12.57 points [-19.40, -5.73]) and 52 weeks (-10.58 points [-17.75, -3.41]). At week 52, tezepelumab reduced blood eosinophil counts and FeNO, IgE, IL-5, IL-13, EDN and MMP-10 levels versus placebo, irrespective of NP status.ResultsTezepelumab reduced the AAER over 52 weeks versus placebo by 85% (95% confidence interval [CI]: 72, 92; n=118) and 51% (95% CI: 40, 60; n=941) in patients with and without NPs, respectively. At week 52, tezepelumab improved lung function, asthma control and HRQoL versus placebo in patients with and without NPs. Tezepelumab reduced SNOT-22 total scores (least-squares mean difference versus placebo [95% CI]) in patients with NPs at 28 weeks (-12.57 points [-19.40, -5.73]) and 52 weeks (-10.58 points [-17.75, -3.41]). At week 52, tezepelumab reduced blood eosinophil counts and FeNO, IgE, IL-5, IL-13, EDN and MMP-10 levels versus placebo, irrespective of NP status.Tezepelumab resulted in clinically meaningful improvements in sino-nasal symptoms and asthma outcomes in patients with severe asthma with comorbid NPs.ConclusionTezepelumab resulted in clinically meaningful improvements in sino-nasal symptoms and asthma outcomes in patients with severe asthma with comorbid NPs. Plain Language Summary: Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing, coughing, wheezing and shortness of breath. Approximately 41% of patients with severe asthma also have chronic rhinosinusitis with nasal polyps, a condition that affects the upper airways and sinuses. Nasal polyps are painless soft growths inside your nose that can keep growing if not treated. Symptoms include nasal congestion with mucus, facial pain and a reduced sense of smell or taste. People with both severe asthma and nasal polyps often have severe symptoms. |
| Audience | Academic |
| Author | Corren, Jonathan Han, Joseph K Laidlaw, Tanya M Martin, Nicole Israel, Elliot Vong, Sylvia Menzies-Gow, Andrew Welte, Tobias Megally, Ayman Caveney, Scott Lee, Jason K Parikh, Bhavini Llanos, Jean-Pierre Martin, Neil |
| Author_xml | – sequence: 1 givenname: Tanya M orcidid: 0000-0001-6709-9795 surname: Laidlaw fullname: Laidlaw, Tanya M – sequence: 2 givenname: Andrew surname: Menzies-Gow fullname: Menzies-Gow, Andrew – sequence: 3 givenname: Scott surname: Caveney fullname: Caveney, Scott – sequence: 4 givenname: Joseph K surname: Han fullname: Han, Joseph K – sequence: 5 givenname: Nicole surname: Martin fullname: Martin, Nicole – sequence: 6 givenname: Elliot orcidid: 0000-0002-2470-856X surname: Israel fullname: Israel, Elliot – sequence: 7 givenname: Jason K surname: Lee fullname: Lee, Jason K – sequence: 8 givenname: Jean-Pierre surname: Llanos fullname: Llanos, Jean-Pierre – sequence: 9 givenname: Neil surname: Martin fullname: Martin, Neil – sequence: 10 givenname: Ayman surname: Megally fullname: Megally, Ayman – sequence: 11 givenname: Bhavini orcidid: 0009-0006-7374-1274 surname: Parikh fullname: Parikh, Bhavini – sequence: 12 givenname: Sylvia surname: Vong fullname: Vong, Sylvia – sequence: 13 givenname: Tobias orcidid: 0000-0002-9947-7356 surname: Welte fullname: Welte, Tobias – sequence: 14 givenname: Jonathan surname: Corren fullname: Corren, Jonathan |
| BookMark | eNptku9rGyEYgI_Rwbqun_YPHAzGYEump-d5n8YRui6jtGVN91X88V5i8c5UTUf3188sYTSjKij6vA-v-r4ujkY_QlG8xWhaYdp8_t510xuKCWL0RXGMccMnrGX10ZP1q-I0xjuUG2kZI-y4sAv4DWtwm0Gq8qzvrZb6sbRjeS2ThTHF8pdNq_IGHiDAp_J21H5MwTsHpuxiWg1yB8z84IOypryUUbry2rvHddx6Lruf8_NucfXjTfGyly7C6X4-KW6_ni1m3yYXV-fzWXcx0XVF0qSVykja8ho4o7pHVUtRrwzTeTCgNeDKYGZoazRGvFFc11wpppTmULHakJNivvMaL-_EOthBhkfhpRV_N3xYChmS1Q5Ei3pMiMFAEKeqrrgBhKRUmHBOdMOy68vOtd6oAYzODxKkO5Aenox2JZb-QWBEeXbgbPiwNwR_v4GYxGCjBufkCH4TRcUZafJX0Caj73boUubc7Nj7rNRbXHQNaynhbU0zNX2Gyt3AYPPnQG_z_kHA-ycBK5AuraJ3m2T9GA_BjztQBx9jgP7fPTES2woTucLEvsIyjf-jtU1yK835WPdszB9p4tO2 |
| CitedBy_id | crossref_primary_10_1007_s12325_024_02889_8 crossref_primary_10_1016_j_ejim_2024_10_015 crossref_primary_10_1016_j_iac_2024_07_006 crossref_primary_10_1056_NEJMoa2414482 crossref_primary_10_1007_s11882_024_01186_2 crossref_primary_10_1016_j_anai_2024_06_033 crossref_primary_10_1016_j_jaci_2025_02_031 crossref_primary_10_15789_1563_0625_CEA_16692 crossref_primary_10_3389_falgy_2024_1517122 crossref_primary_10_1016_j_rmcr_2024_102041 crossref_primary_10_1007_s12325_024_03006_5 crossref_primary_10_1016_j_anai_2024_02_024 crossref_primary_10_1016_j_resinv_2024_11_010 crossref_primary_10_1177_03000605241297532 crossref_primary_10_1186_s12931_024_02998_6 crossref_primary_10_21508_1027_4065_2024_69_4_11_15 crossref_primary_10_1016_j_jacig_2024_100396 crossref_primary_10_1016_j_bjorl_2024_101394 crossref_primary_10_1080_14712598_2024_2342527 crossref_primary_10_1080_1744666X_2025_2459929 crossref_primary_10_1016_j_iac_2024_07_005 crossref_primary_10_1080_14712598_2024_2370397 crossref_primary_10_3390_biomedicines12112647 crossref_primary_10_1016_j_jaci_2024_01_015 |
| Cites_doi | 10.1056/NEJMoa1704064 10.1186/s41687-019-0109-2 10.1371/journal.pone.0127228 10.1002/lary.29766 10.1016/j.anai.2021.01.012 10.1016/j.jaci.2019.03.026 10.1016/j.chest.2020.03.042 10.3390/cells10082012 10.1016/j.jaci.2020.05.032 10.1016/j.humimm.2012.11.004 10.1016/j.jaci.2016.08.040 10.1016/j.jaci.2010.12.557 10.1016/j.jaci.2015.10.020 10.1016/j.jaci.2013.04.005 10.1126/science.aaw4295 10.1016/j.rmed.2020.105947 10.1111/j.1749-4486.2009.01995.x 10.1007/s12016-021-08844-7 10.1002/lary.23979 10.2500/ajra.2009.23.3284 10.1016/j.jaci.2013.04.050 10.3390/jpm12081304 10.1016/j.jaip.2022.05.013 10.3390/medicina55040095 10.3389/fimmu.2018.01595 10.1016/j.alit.2019.06.007 10.1016/S2213-2600(21)00226-5 10.1016/j.jaci.2016.05.041 10.1016/j.jaci.2020.02.002 10.1159/000447692 10.1111/j.1365-2222.2005.02194.x 10.1016/S2213-2600(20)30414-8 10.1183/13993003.02420-2019 10.1111/cea.12304 10.1016/j.jaip.2021.08.004 10.4193/Rhin20.600 10.1371/journal.pone.0152808 10.4168/aair.2011.3.3.186 10.1002/iid3.161 10.1080/14728222.2020.1783242 10.1183/13993003.congress-2018.PA1125 10.1016/j.jaci.2019.12.820 10.1111/all.13552 10.1378/chest.115.5.1265 10.1016/j.jaip.2020.10.010 10.1111/all.15197 10.1016/j.anai.2022.11.006 10.1016/j.jaci.2022.02.016 10.1016/j.jaip.2020.09.063 10.1016/j.rmed.2020.106080 10.2147/JAA.S290424 10.1002/lary.27564 10.4193/Rhin17.045 10.1016/j.jaci.2011.12.986 10.1016/j.jaci.2022.04.034 10.1002/alr.21486 10.2500/ajra.2013.27.3981 10.1016/j.jaci.2019.12.808 10.1126/sciimmunol.abb7221 10.1002/alr.22028 10.1177/014556130708600719 10.1159/000346929 10.18176/jiaci.0391 10.1016/j.jaci.2014.12.1196 10.1038/mi.2014.126 10.1111/j.1398-9995.2011.02709.x 10.1056/NEJMoa2034975 10.2147/jaa.S288260 10.1038/s41577-022-00735-y 10.1002/clt2.12059 10.1056/NEJMoa1402895 10.1016/j.jaip.2019.05.009 10.1016/j.jaip.2019.07.016 10.1016/j.jaci.2019.08.027 10.1177/1945892419846263 10.1016/j.jaci.2011.12.755 10.2147/JAA.S363527 10.1165/rcmb.2017-0325OC 10.1007/s00405-019-05379-8 10.1165/rcmb.2009-0168OC 10.1007/s11882-015-0589-y 10.5414/alx02296e 10.3389/fphys.2019.01514 10.1084/jem.20062211 10.1186/s13601-020-00332-z 10.1080/13543784.2019.1672657 10.1111/all.14902 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2023 Dove Medical Press Limited 2023 Laidlaw et al. 2023 Laidlaw et al. 2023 Laidlaw et al. |
| Copyright_xml | – notice: COPYRIGHT 2023 Dove Medical Press Limited – notice: 2023 Laidlaw et al. – notice: 2023 Laidlaw et al. 2023 Laidlaw et al. |
| DBID | AAYXX CITATION 7X8 5PM DOA |
| DOI | 10.2147/JAA.S413064 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Laidlaw et al |
| EISSN | 1178-6965 |
| EndPage | 932 |
| ExternalDocumentID | oai_doaj_org_article_90f133d1e3084b528de00aab13883c76 PMC10488831 A769438954 10_2147_JAA_S413064 |
| GeographicLocations | United States Illinois China United Kingdom Israel France Switzerland |
| GeographicLocations_xml | – name: Israel – name: United Kingdom – name: Switzerland – name: China – name: United States – name: Illinois – name: France |
| GrantInformation_xml | – fundername: ; |
| GroupedDBID | --- 0YH 29J 2WC 5VS 7RV 8C1 8FE 8FH 8FI 8FJ 8G5 AAYXX ABUWG ACGFO ADBBV ADRAZ AFKRA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BBNVY BCNDV BENPR BHPHI BKEYQ BPHCQ BVXVI CCPQU CITATION DIK DWQXO E3Z EBD EBS EJD FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HYE IAO IHR IHW IPNFZ ITC KQ8 LK8 M2O M48 M7P M~E NAPCQ O5R O5S OK1 P2P P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RIG RNS RPM TDBHL TR2 UKHRP VDV PMFND 7X8 PJZUB PPXIY PQGLB PUEGO 5PM |
| ID | FETCH-LOGICAL-c523t-9abda4985e864cf02940fbd6cd6c6e45e12d16d49dc1087b8c58bb6bbc8e265d3 |
| IEDL.DBID | M48 |
| ISSN | 1178-6965 |
| IngestDate | Wed Aug 27 00:57:31 EDT 2025 Thu Aug 21 18:36:33 EDT 2025 Thu Sep 04 22:51:11 EDT 2025 Tue Jun 17 22:19:57 EDT 2025 Tue Jun 10 21:28:01 EDT 2025 Thu May 22 21:30:50 EDT 2025 Tue Jul 01 03:31:29 EDT 2025 Thu Apr 24 23:03:21 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc/3.0 This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c523t-9abda4985e864cf02940fbd6cd6c6e45e12d16d49dc1087b8c58bb6bbc8e265d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work |
| ORCID | 0000-0001-6709-9795 0000-0002-9947-7356 0009-0006-7374-1274 0000-0002-2470-856X |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.2147/JAA.S413064 |
| PQID | 2863766347 |
| PQPubID | 23479 |
| PageCount | 18 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_90f133d1e3084b528de00aab13883c76 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10488831 proquest_miscellaneous_2863766347 gale_infotracmisc_A769438954 gale_infotracacademiconefile_A769438954 gale_healthsolutions_A769438954 crossref_primary_10_2147_JAA_S413064 crossref_citationtrail_10_2147_JAA_S413064 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20230930 |
| PublicationDateYYYYMMDD | 2023-09-30 |
| PublicationDate_xml | – month: 09 year: 2023 text: 20230930 day: 30 |
| PublicationDecade | 2020 |
| PublicationTitle | Journal of asthma and allergy |
| PublicationYear | 2023 |
| Publisher | Dove Medical Press Limited Dove Dove Medical Press |
| Publisher_xml | – name: Dove Medical Press Limited – name: Dove – name: Dove Medical Press |
| References | Seybt (ref4) 2007; 86 Bagnasco (ref26) 2020; 171 Gevaert (ref83) 2020; 146 Kimura (ref47) 2011; 3 Laidlaw (ref34) 2019; 129 Kato (ref52) 2012; 129 Poposki (ref63) 2017; 5 Tepper (ref74) 2012; 129 Håkansson (ref16) 2015; 10 Howarth (ref24) 2020; 145 Gallo (ref29) 2022; 12 Wong (ref59) 2010; 43 Klimek (ref38) 2022; 6 Katainen (ref14) 2015; 5 Jarvis (ref3) 2012; 67 Ahern (ref35) 2019; 55 Kato (ref54) 2022; 149 Globe (ref77) 2019; 3 Vanderhaegen (ref8) 2022; 62 Maspero (ref90) 2020; 8 Pearlman (ref9) 2009; 23 Canonica (ref5) 2020; 166 Laidlaw (ref6) 2021; 9 Yan (ref19) 2019; 144 Nocera (ref61) 2022; 150 Wang (ref62) 2018; 56 Emson (ref73) 2021; 14 Laidlaw (ref30) 2021; 126 Hui (ref43) 2015; 8 Khan (ref81) 2022; 132 Gauvreau (ref40) 2020; 24 Bagnasco (ref86) 2016; 170 Canonica (ref21) 2022; 77 Tiotiu (ref22) 2020; 30 Corren (ref68) 2017; 377 Allakhverdi (ref39) 2007; 204 Chowdhury (ref78) 2017; 7 Berger (ref28) 2023; 130 Kato (ref60) 2018; 59 Tint (ref2) 2016; 16 Zhang (ref44) 2013; 74 Gauvreau (ref66) 2014; 370 Hopkins (ref79) 2009; 34 Lan (ref42) 2015; 135 ref75 Braile (ref58) 2021; 10 Han (ref10) 2013; 123 Suppl 2 Radabaugh (ref11) 2019; 33 Nakayama (ref45) 2020; 69 Ediger (ref20) 2005; 35 Bickel (ref87) 1993; 64 Cao (ref51) 2011; 127 Kanemitsu (ref15) 2013; 132 Menzies-Gow (ref69) 2021; 384 Wang (ref18) 2020; 10 Du (ref13) 2021; 11 Varricchi (ref37) 2018; 9 Ouyang (ref50) 2013; 75 Buchheit (ref57) 2016; 137 Bachert (ref7) 2021; 14 Busse (ref84) 2022; 10 Chaaban (ref17) 2013; 27 Ebina-Shibuya (ref36) 2022; 23 ref72 Juniper (ref76) 1999; 115 Busse (ref82) 2018; 52 Harvey (ref33) 2020; 55 Diver (ref71) 2021; 9 Eger (ref32) 2021; 9 Cao (ref55) 2014; 44 Jain (ref89) 2020; 145 Harrison (ref23) 2021; 9 Dwyer (ref56) 2021; 6 Corren (ref70) 2022; 77 Stevens (ref1) 2019; 7 Dogan (ref46) 2019; 276 Hopkins (ref27) 2022; 15 Ogasawara (ref49) 2018; 73 Gevaert (ref64) 2020; 145 Marone (ref67) 2019; 28 Nagarkar (ref48) 2013; 132 Golebski (ref41) 2016; 11 Persson (ref65) 2019; 364 Wang (ref88) 2016; 138 Pham (ref80) 2020; 145 Fokkens (ref12) 2020; 58 Nolasco (ref25) 2021; 9 Pelaia (ref85) 2019; 10 Kavanagh (ref31) 2020; 158 Poposki (ref53) 2017; 139 |
| References_xml | – volume: 377 start-page: 936 year: 2017 ident: ref68 publication-title: N Engl J Med doi: 10.1056/NEJMoa1704064 – volume: 3 start-page: 22 year: 2019 ident: ref77 publication-title: J Patient Rep Outcomes doi: 10.1186/s41687-019-0109-2 – volume: 10 start-page: e0127228 year: 2015 ident: ref16 publication-title: PLoS One doi: 10.1371/journal.pone.0127228 – volume: 132 start-page: 933 year: 2022 ident: ref81 publication-title: Laryngoscope doi: 10.1002/lary.29766 – volume: 126 start-page: 584 year: 2021 ident: ref30 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2021.01.012 – volume: 144 start-page: 455 year: 2019 ident: ref19 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.03.026 – volume: 158 start-page: 491 year: 2020 ident: ref31 publication-title: Chest doi: 10.1016/j.chest.2020.03.042 – volume: 10 start-page: 2012 year: 2021 ident: ref58 publication-title: Cells doi: 10.3390/cells10082012 – volume: 146 start-page: 595 year: 2020 ident: ref83 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.05.032 – volume: 74 start-page: 241 year: 2013 ident: ref44 publication-title: Hum Immunol doi: 10.1016/j.humimm.2012.11.004 – volume: 139 start-page: 1559 year: 2017 ident: ref53 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.08.040 – ident: ref72 – volume: 127 start-page: AB140 year: 2011 ident: ref51 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2010.12.557 – volume: 137 start-page: 1566 year: 2016 ident: ref57 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2015.10.020 – volume: 132 start-page: 593 year: 2013 ident: ref48 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.04.005 – volume: 364 start-page: eaaw4295 year: 2019 ident: ref65 publication-title: Science doi: 10.1126/science.aaw4295 – volume: 166 start-page: 105947 year: 2020 ident: ref5 publication-title: Respir Med doi: 10.1016/j.rmed.2020.105947 – volume: 34 start-page: 447 year: 2009 ident: ref79 publication-title: Clin Otolaryngol doi: 10.1111/j.1749-4486.2009.01995.x – volume: 62 start-page: 90 year: 2022 ident: ref8 publication-title: Clin Rev Allergy Immunol doi: 10.1007/s12016-021-08844-7 – volume: 123 Suppl 2 start-page: S15 year: 2013 ident: ref10 publication-title: Laryngoscope doi: 10.1002/lary.23979 – volume: 23 start-page: 145 year: 2009 ident: ref9 publication-title: Am J Rhinol Allergy doi: 10.2500/ajra.2009.23.3284 – volume: 64 start-page: 456 year: 1993 ident: ref87 publication-title: J Periodontol – volume: 132 start-page: 305 year: 2013 ident: ref15 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2013.04.050 – volume: 12 start-page: 1304 year: 2022 ident: ref29 publication-title: J Pers Med doi: 10.3390/jpm12081304 – volume: 10 start-page: 2479 year: 2022 ident: ref84 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2022.05.013 – volume: 55 start-page: 95 year: 2019 ident: ref35 publication-title: Medicina doi: 10.3390/medicina55040095 – volume: 9 start-page: 1595 year: 2018 ident: ref37 publication-title: Front Immunol doi: 10.3389/fimmu.2018.01595 – volume: 69 start-page: 138 year: 2020 ident: ref45 publication-title: Allergol Int doi: 10.1016/j.alit.2019.06.007 – volume: 9 start-page: 1299 year: 2021 ident: ref71 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(21)00226-5 – volume: 138 start-page: 1344 year: 2016 ident: ref88 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2016.05.041 – volume: 145 start-page: 1713 year: 2020 ident: ref24 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2020.02.002 – volume: 170 start-page: 122 year: 2016 ident: ref86 publication-title: Int Arch Allergy Immunol doi: 10.1159/000447692 – volume: 35 start-page: 319 year: 2005 ident: ref20 publication-title: Clin Exp Allergy doi: 10.1111/j.1365-2222.2005.02194.x – volume: 9 start-page: 260 year: 2021 ident: ref23 publication-title: Lancet Respir Med doi: 10.1016/S2213-2600(20)30414-8 – volume: 55 start-page: 1902420 year: 2020 ident: ref33 publication-title: Eur Respir J doi: 10.1183/13993003.02420-2019 – ident: ref75 – volume: 44 start-page: 690 year: 2014 ident: ref55 publication-title: Clin Exp Allergy doi: 10.1111/cea.12304 – volume: 9 start-page: 4371 year: 2021 ident: ref25 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2021.08.004 – volume: 58 start-page: 1 year: 2020 ident: ref12 publication-title: Rhinology doi: 10.4193/Rhin20.600 – volume: 11 start-page: e0152808 year: 2016 ident: ref41 publication-title: PLoS One doi: 10.1371/journal.pone.0152808 – volume: 3 start-page: 186 year: 2011 ident: ref47 publication-title: Allergy Asthma Immunol Res doi: 10.4168/aair.2011.3.3.186 – volume: 5 start-page: 233 year: 2017 ident: ref63 publication-title: Immun Inflamm Dis doi: 10.1002/iid3.161 – volume: 24 start-page: 777 year: 2020 ident: ref40 publication-title: Expert Opin Ther Targets doi: 10.1080/14728222.2020.1783242 – volume: 52 start-page: PA1125 year: 2018 ident: ref82 publication-title: Eur Resp J doi: 10.1183/13993003.congress-2018.PA1125 – volume: 145 start-page: AB30 year: 2020 ident: ref80 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.12.820 – volume: 73 start-page: 2251 year: 2018 ident: ref49 publication-title: Allergy doi: 10.1111/all.13552 – volume: 115 start-page: 1265 year: 1999 ident: ref76 publication-title: Chest doi: 10.1378/chest.115.5.1265 – volume: 9 start-page: 1194 year: 2021 ident: ref32 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.10.010 – volume: 77 start-page: 1786 year: 2022 ident: ref70 publication-title: Allergy doi: 10.1111/all.15197 – volume: 130 start-page: 215 year: 2023 ident: ref28 publication-title: Ann Allergy Asthma Immunol doi: 10.1016/j.anai.2022.11.006 – volume: 149 start-page: 1491 year: 2022 ident: ref54 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2022.02.016 – volume: 9 start-page: 1133 year: 2021 ident: ref6 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2020.09.063 – volume: 171 start-page: 106080 year: 2020 ident: ref26 publication-title: Respir Med doi: 10.1016/j.rmed.2020.106080 – volume: 14 start-page: 127 year: 2021 ident: ref7 publication-title: J Asthma Allergy doi: 10.2147/JAA.S290424 – volume: 129 start-page: E61 year: 2019 ident: ref34 publication-title: Laryngoscope doi: 10.1002/lary.27564 – volume: 56 start-page: 370 year: 2018 ident: ref62 publication-title: Rhinology doi: 10.4193/Rhin17.045 – volume: 129 start-page: S65 year: 2012 ident: ref74 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.12.986 – volume: 150 start-page: 872 year: 2022 ident: ref61 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2022.04.034 – volume: 5 start-page: 294 year: 2015 ident: ref14 publication-title: Int Forum Allergy Rhinol doi: 10.1002/alr.21486 – volume: 27 start-page: 473 year: 2013 ident: ref17 publication-title: Am J Rhinol Allergy doi: 10.2500/ajra.2013.27.3981 – volume: 145 start-page: AB26 year: 2020 ident: ref89 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.12.808 – volume: 6 start-page: eabb7221 year: 2021 ident: ref56 publication-title: Sci Immunol doi: 10.1126/sciimmunol.abb7221 – volume: 7 start-page: 1149 year: 2017 ident: ref78 publication-title: Int Forum Allergy Rhinol doi: 10.1002/alr.22028 – volume: 86 start-page: 409 year: 2007 ident: ref4 publication-title: Ear Nose Throat J doi: 10.1177/014556130708600719 – volume: 75 start-page: 37 year: 2013 ident: ref50 publication-title: ORL J Otorhinolaryngol Relat Spec doi: 10.1159/000346929 – volume: 30 start-page: 49 year: 2020 ident: ref22 publication-title: J Investig Allergol Clin Immunol doi: 10.18176/jiaci.0391 – volume: 135 start-page: AB81 year: 2015 ident: ref42 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2014.12.1196 – volume: 8 start-page: 993 year: 2015 ident: ref43 publication-title: Mucosal Immunol doi: 10.1038/mi.2014.126 – volume: 67 start-page: 91 year: 2012 ident: ref3 publication-title: Allergy doi: 10.1111/j.1398-9995.2011.02709.x – volume: 384 start-page: 1800 year: 2021 ident: ref69 publication-title: N Engl J Med doi: 10.1056/NEJMoa2034975 – volume: 14 start-page: 91 year: 2021 ident: ref73 publication-title: J Asthma Allergy doi: 10.2147/jaa.S288260 – volume: 23 start-page: 24 year: 2022 ident: ref36 publication-title: Nat Rev Immunol doi: 10.1038/s41577-022-00735-y – volume: 11 start-page: e12059 year: 2021 ident: ref13 publication-title: Clin Transl Allergy doi: 10.1002/clt2.12059 – volume: 370 start-page: 2102 year: 2014 ident: ref66 publication-title: N Engl J Med doi: 10.1056/NEJMoa1402895 – volume: 7 start-page: 2812 year: 2019 ident: ref1 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2019.05.009 – volume: 8 start-page: 527 year: 2020 ident: ref90 publication-title: J Allergy Clin Immunol Pract doi: 10.1016/j.jaip.2019.07.016 – volume: 145 start-page: 427 year: 2020 ident: ref64 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2019.08.027 – volume: 33 start-page: 507 year: 2019 ident: ref11 publication-title: Am J Rhinol Allergy doi: 10.1177/1945892419846263 – volume: 129 start-page: AB70 year: 2012 ident: ref52 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2011.12.755 – volume: 15 start-page: 767 year: 2022 ident: ref27 publication-title: J Asthma Allergy doi: 10.2147/JAA.S363527 – volume: 59 start-page: 448 year: 2018 ident: ref60 publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2017-0325OC – volume: 276 start-page: 1685 year: 2019 ident: ref46 publication-title: Eur Arch Otorhinolaryngol doi: 10.1007/s00405-019-05379-8 – volume: 43 start-page: 305 year: 2010 ident: ref59 publication-title: Am J Respir Cell Mol Biol doi: 10.1165/rcmb.2009-0168OC – volume: 16 start-page: 16 year: 2016 ident: ref2 publication-title: Curr Allergy Asthma Rep doi: 10.1007/s11882-015-0589-y – volume: 6 start-page: 148 year: 2022 ident: ref38 publication-title: Allergol Select doi: 10.5414/alx02296e – volume: 10 start-page: 1514 year: 2019 ident: ref85 publication-title: Front Physiol doi: 10.3389/fphys.2019.01514 – volume: 204 start-page: 253 year: 2007 ident: ref39 publication-title: J Exp Med doi: 10.1084/jem.20062211 – volume: 10 start-page: 26 year: 2020 ident: ref18 publication-title: Clin Transl Allergy doi: 10.1186/s13601-020-00332-z – volume: 28 start-page: 931 year: 2019 ident: ref67 publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2019.1672657 – volume: 77 start-page: 150 year: 2022 ident: ref21 publication-title: Allergy doi: 10.1111/all.14902 |
| SSID | ssj0000396636 |
| Score | 2.4426234 |
| Snippet | Purpose: Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced... Plain Language Summary: Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing,... Tezepelumab, a human monoclonal antibody, blocks thymic stromal lymphopoietin. In the phase 3 NAVIGATOR study (NCT03347279), tezepelumab reduced annualized... Asthma is a long-term condition caused by ongoing inflammation of the lower airways. The main symptoms are difficulty breathing, coughing, wheezing and... Tanya M Laidlaw1,2 *, Andrew Menzies-Gow3 *, Scott Caveney,4 Joseph K Han,5 Nicole Martin,6,7 Elliot Israel,8 Jason K Lee,9,10 Jean-Pierre Llanos,11 Neil... |
| SourceID | doaj pubmedcentral proquest gale crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 915 |
| SubjectTerms | Analysis Asthma Care and treatment chronic rhinosinusitis Comorbidity Immunoglobulin E Inflammation Interleukins Medical research Medicine, Experimental Monoclonal antibodies Nasal polyps Nitric oxide Nurse practitioners Original Research Pain Pharmaceutical industry snot-22 thymic stromal lymphopoietin |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh9JLafqg2yatAoFCqRvJkmXp6JY8Gsg2NLslN6GXycLWu8SbQ_LrM7KcZd0Wein4ZA2WNS9p7JlvENrnpHaSMZuponYZh3Atk742WahzJS1VgbNY73w2FidTfnpZXG60-oo5YQkeODHuQJEawihPAyOS2yKXPhBijKVMSubKDmwbtrGNYKrzwQyO8V1_QEohTBJKFKk4L7blOTitqs8X0XsLPtiOOtT-P33z7_mSGxvQ0TP0tD854iq98TZ6FJrn6PFZ_2_8BZpNwl1YBnA2xuLDiAxh3C2eNfg8Qae2OH5zxRcBlDd8wtOmz1KfB4-rdnX1yyQC8BCLazvzeGxamO98Mb9dtvE54-rnt-Nq8v3HSzQ9Opx8Pcn6RgqZgzhzlSljveFKFkEK7mqSKxCR9cLBJQIvAs09FZ4r7yiRpZWukNYKa50MuSg8e4W2mkUTXiMMIpXE155IV3bRlyHB2pxLxwRzlI3Qxwd-atejjMdmF3MN0UZkvgbm6575I7S_Jl4mcI2_k32JglmTRETs7gboie71RP9LT0bofRSrTuWla7vWVSlU7ABfwDQfOopo2fDKIKRUoAALjxhZA8qdASVYpBsM7z2ojo5DMY2tCYubVudSgEMXjJcjJAc6NVjccKSZXXWw3zQ6W8nom__BjrfoSQ7HtZT5soO2Vtc3YReOVyv7rrOke1e_IIg priority: 102 providerName: Directory of Open Access Journals |
| Title | Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR |
| URI | https://www.proquest.com/docview/2863766347 https://pubmed.ncbi.nlm.nih.gov/PMC10488831 https://doaj.org/article/90f133d1e3084b528de00aab13883c76 |
| Volume | 16 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: KQ8 dateStart: 20080101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: DOA dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: DIK dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: GX1 dateStart: 20080101 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: GX1 dateStart: 0 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: M~E dateStart: 20080101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: RPM dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: BENPR dateStart: 20080101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: 8C1 dateStart: 20080101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 1178-6965 dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: M48 dateStart: 20080901 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal – providerCode: PRVAWR databaseName: Taylor & Francis Open Access customDbUrl: eissn: 1178-6965 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0000396636 issn: 1178-6965 databaseCode: 0YH dateStart: 20081201 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhR1ra9swUPQBY1_Gnixbl2lQGIy5kyxZlj-M4ZZ0WSFZaJPRfRLWw20gc7I4hWW_fifbCXNXGBh_sM6WdS_d2fdA6JCT3EjGdJBEuQk4uGuBtHkWuDxMpKaJ48znOw-Goj_hZ5fR5Q7aNONsEFje6dr5flKT5ezo18_1JxD4jz6MmfL4w1maHl14ZSz4LtqHLSn07D1o7PxKJTOw6qt2gZSC1yQSEdW5erfvb-1OVRH_f1X17fDJv_aj04foQWNI4rSm_CO044rH6N6g-VX-BE3H7rdbONA9mcY9XygiM2s8LfCorqRaYv8JFl844GX3Hk-KJmh95ixOy9X1j6wGAIUxX-qpxcOshPlG89l6UfrnDNNvXz6n46_nT9HktDc-6QdNX4XAgNu5CpJM24wnMnJScJOTMAGKaSsMHMLxyNHQUmF5Yg0lMtbSRFJrobWRLhSRZc_QXjEv3HOEgcKS2NwSaeLKGcuI0zrk0jDBDGUd9G6DT2WaouO-98VMgfPhka8A-apBfgcdboEXda2Nu8GOPWG2IL5AdnVhvrxSjbyphOTgfVvqGJFcR6G0jpAs05RJyUwsOui1J6uqs023Yq7SWCS-IXwE07ytIDzrwSsDkep8BVi4L5nVgjxoQYKAmtbwmw3rKD_ko9oKN78pVSgF6HfBeNxBssVTrcW1R4rpdVUFnHrdKxl98d-VvET3QzDN6iiXA7S3Wt64V2BKrXQX7ZLvfTjLE9pF-8e94ei8W32W6FYC9AdhbyAl |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tezepelumab+Efficacy+in+Patients+with+Severe%2C+Uncontrolled+Asthma+with+Comorbid+Nasal+Polyps+in+NAVIGATOR&rft.jtitle=Journal+of+asthma+and+allergy&rft.au=Welte%2C+Tobias&rft.au=Lee%2C+Jason+K&rft.au=Caveney%2C+Scott&rft.au=Menzies-Gow%2C+Andrew&rft.date=2023-09-30&rft.pub=Dove+Medical+Press+Limited&rft.issn=1178-6965&rft.eissn=1178-6965&rft.volume=16&rft.spage=915&rft_id=info:doi/10.2147%2FJAA.S413064&rft.externalDBID=n%2Fa&rft.externalDocID=A769438954 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1178-6965&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1178-6965&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1178-6965&client=summon |